Nanoparticle delivery of an akt/pdk1 inhibitor improves the therapeutic effect in pancreatic cancer

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5653-5665

  Lucero Acuña, Armando ^a   Jeffery, Justin J ^a   Abril, Edward R ^b,c   Nagle, Raymond B ^b,c   Guzman, Roberto ^a   Pagel, Mark D ^a,b,c,d   Meuillet, Emmanuelle J ^b,e,f  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d University of Arizona   (United States)

^e University of Arizona   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; PH 427; POLYGLACTIN; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NANOENCAPSULATION; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; FLUORESCENCE IMAGING; METABOLISM; PANCREAS TUMOR; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, SCID; NANOPARTICLES; OPTICAL IMAGING; PANCREATIC NEOPLASMS; POLYGLYCOLIC ACID; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84914675536     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S68511     Document Type: Article

References (47)

1. Kollmannsberger C, Peters HD, Fink U. Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat Rev. 1998;24:133–156.
2. Dimou A, Syrigos KN, Saif MW. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol. 2012;4:271–279.
3. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186–1197.
4. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617.
5. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–1461.
6. Heid I, Lubeseder-Martellato C, Sipos B, et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology. 2011;141:719–730.
7. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71: 5020–5029.
8. Ijichi H. Genetically-engineered mouse models for pancreatic cancer. World J Clin Oncol. 2011;2:195–202.
9. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocar­cinoma. Genes Dev. 2002;17:3112–3126.
10. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Onco­genic Kras-induced GM-CSF production promotes the development of pancreatic cancer. Cancer Cell. 2012;21:836–847.
11. Grippo PJ, Fitchev PS, Bentrem DJ, et al. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012;61:1454–1464.
12. Moses SA, Ali MA, Zuohe S, et al. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 2009;69:5073–5081.
13. Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010;9:706–717.
14. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitization in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer. 2003;89:391–397.
15. Mortenson MM, Galante JM, Schlieman MG, Bold RJ. AKT: a novel target in pancreatic cancer therapy. Cancer Ther. 2004;2:227–238.
16. Wei F, Liu Y, Bellail AC, et al. K-ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resis­tance in pancreatic ductal adenocarcinomas. Cancer Lett. 2012;322: 58–69.
17. Jing J, Greshock J, Holbrook JD, et al. Comprehensive predictive bio­marker analysis for MEK inhibitor GSK11202Mol Cancer Ther. 2012;11:720–729.
18. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res. 2011;17:2744–2756.
19. Kelber JA, Reno T, Kaushal S, et al. Kras induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res. 2012;72:2554–2564.
20. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16:108–123.
21. Jain RA. The manufacturing techniques of various drug loaded bio­degradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21:2475–2490.
22. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanopar­ticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010; 75:1–18.
23. Cascone MG, Zhu Z, Borselli F, Lazzeri L. Poly(vinyl alcohol) hydro­gels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles. J Mater Sci Mater Med. 2002;13:29–32.
24. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. Powder Technol. 2000;107:137–143.
25. Sahana DK, Mittal G, Bhardwaj V, Kumar MN. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci. 2008;97:1530–1542.
26. Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release. 2002;83:389–400.
27. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105:17356–17361.
28. Park J, Fong PM, Lu J, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 2009;5:410–418.
29. Lei T, Srinivasan S, Tang Y, et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine. 2011;7:324–332.
30. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nano­particle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 2002;79:123–135.
31. Liang C, Yang Y, Ling Y, Huang Y, Li T, Li X. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorgan Med Chem. 2011;19:4057–4066.
32. Wendt MK, Molter J, Flask CA, Schiemann WP. In vivo dual substrate bioluminescent imaging. J Vis Exp. 2011;56:3245.
33. Bentancourt T, Shah K, Brannon-Peppas L. Rhodamine-loaded poly(lactic-co-glycolic acid) nanoparticles for investigation of in vitro interactions with breast cancer cells. J Mater Sci Mater Med. 2009;20:387–395.
34. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials. 2009;30:2790–2798.
35. Tuli R, Surmak A, Reyes J, Hacker-Prietz A, Armour M, Leubner A. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. Transl Oncol. 2012;5:77–84.
36. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanopar­ticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010; 75:1–18.
37. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59:718–728.
38. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol. 2009;174:854–868.
39. Morishita A, Zaidi MR, Mitoro A, et al. HMGA2 is a driver of tumor metastasis. Mol Cell Pathol. 2013;73:4289–4299.
40. Pamujula S, Hazari S, Bolden G, et al. Preparation and in-vitro/in-vivo evaluation of surface-modified poly(lactide-co-glycolide) fluorescent nanoparticles. J Pharm Pharmacol. 2010;62:422–429.
41. Ding H, Yong KT, Roy I, et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology. 2011;22:165101.
42. Teni B. Clinical overview on lipoplatin: a successful liposomal formula­tion of cisplatin. Expert Opin Investig Drugs. 2009;18:1197–1218.
43. Casaluce F, Sgambato A, Maione P, Ciardiello F, Gridelli C. Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opin Emerg Drugs. 2013;18:97–107.
44. Yang F, Jin C, Subedi SL, et al. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev. 2012;38: 566–579.
45. Yu X, Zhang Y, Chen C, Yao Q, Li M. Targeted drug delivery in pan­creatic cancer. Biochim Biophys Acta. 2010;1805:97–104.
46. Werner ME, Foote MB, Wang AZ. Chemoradiotherapy of human tumors: novel approaches from nanomedicine. Curr Pharm Des. 2012; 18:2830–2837.
47. Xu J, Jin C, Hao S-J, Luo G-P, Fu D-L. Pancreatic cancer: gene therapy approaches and gene delivery systems. Expert Opin Biol Ther. 2010; 10:73–88.